Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$27.97
+1.3%
$20.96
$16.10
$41.94
$3.53B0.783.15 million shs1.82 million shs
Immunome, Inc. stock logo
IMNM
Immunome
$10.30
+3.5%
$9.69
$5.15
$16.73
$896.56M1.93605,789 shs1.04 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$55.89
+3.2%
$50.51
$31.42
$58.26
$3.59B1.27469,826 shs257,570 shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$57.48
+2.6%
$54.15
$33.31
$60.60
$3.58B2.33605,768 shs470,129 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%+0.79%+39.22%+60.38%-29.82%
Immunome, Inc. stock logo
IMNM
Immunome
0.00%+0.19%-8.36%+21.32%-32.24%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.00%+2.76%+1.56%+43.57%+13.30%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%+2.51%+6.96%+25.89%+38.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.1708 of 5 stars
3.31.00.04.43.52.50.6
Immunome, Inc. stock logo
IMNM
Immunome
1.8202 of 5 stars
3.50.00.00.02.72.50.0
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1.6421 of 5 stars
3.41.00.00.01.32.50.0
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
1.801 of 5 stars
2.53.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.58
Moderate Buy$34.1221.98% Upside
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$22.50118.45% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.78
Moderate Buy$74.4333.17% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$67.2016.91% Upside

Current Analyst Ratings Breakdown

Latest IMNM, APLS, MLTX, and PTGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Immunome, Inc. stock logo
IMNM
Immunome
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
8/7/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/7/2025
Immunome, Inc. stock logo
IMNM
Immunome
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$23.00 ➝ $22.00
8/7/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00
8/7/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$67.00 ➝ $69.00
8/6/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$74.00 ➝ $82.00
8/4/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$35.00 ➝ $37.00
8/1/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $19.00
8/1/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$39.00 ➝ $40.00
8/1/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$52.00 ➝ $50.00
7/29/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$41.00 ➝ $46.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M4.52N/AN/A$1.24 per share22.56
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M99.17N/AN/A$3.09 per share3.33
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$5.57 per shareN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M8.23$4.52 per share12.72$10.74 per share5.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.7082.12N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)

Latest IMNM, APLS, MLTX, and PTGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 million
8/6/2025Q2 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million
8/5/2025Q2 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.73-$0.87-$0.14-$0.87N/AN/A
7/31/2025Q2 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.90
3.77
3.16
Immunome, Inc. stock logo
IMNM
Immunome
N/A
12.13
12.13
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.21
16.65
16.65
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
16.97
16.97

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770126.29 million118.08 millionOptionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.04 million80.35 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
264.23 million56.51 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12062.21 million59.16 millionOptionable

Recent News About These Companies

Wedbush Has Positive Estimate for PTGX Q3 Earnings
Protagonist (PTGX) Q2 Revenue Falls 26%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$27.97 +0.35 (+1.27%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$27.92 -0.04 (-0.16%)
As of 08/22/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Immunome stock logo

Immunome NASDAQ:IMNM

$10.30 +0.35 (+3.52%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$10.30 +0.00 (+0.05%)
As of 08/22/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$55.89 +1.72 (+3.18%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$54.75 -1.14 (-2.04%)
As of 08/22/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$57.48 +1.44 (+2.57%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$57.48 +0.01 (+0.01%)
As of 08/22/2025 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.